“It’s Gettin’ Rocky!” Vista Partners Weekly Market Update 8-18-18

Vista Partners has published “It’s Gettin’ Rocky!” Vista Partners Weekly Market Update 8-18-18 and is accessible on our Newsletters Page. Each issue is written by the Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Breast Cancer Treatment Innovator Atossa Genetics Announces “A Productive First Six Months of 2018”

Seattle-based Atossa Genetics Inc. (ATOS) is  a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced their Q2 ended June 30, 2018, financial results and recent company developments which included the following:

  • August 2018 – Contracted with a US-based additional manufacturer of Endoxifen.
  • July 2018 – Announced intraductal microcatheter immunoOncology pre-clinical program.
  • July 2018 – Opened enrollment in phase 2 study of oral Endoxifen to treat breast cancer.
  • June 2018 – Opened phase 2 study of topical Endoxifen to treat mammographic breast density.
  • June 2018 – Completed all dosing and clinical visits in its phase 1 study of topical Endoxifen in men.
  • June 2018 – Appointed two additional prominent industry executives from Pfizer and the Belgium-based Flemish Institute of Biotechnology to the strategic advisory board.
  • May 2018 – Announced $13.4 million in gross proceeds from the rights offering.
  • May 2018 – Formed strategic advisory board to accelerate growth with prominent former pharmaceutical executives from Pfizer and Boehringer Ingelheim.
  • April 2018 – Received a positive interim safety review on the Phase 1 study of topical Endoxifen in men.
    Q2 2018 Financial Results
  • For the three and six months ended June 30, 2018, and 2017, they had no revenue and no associated cost of revenue.
  • Total operating expenses were approximately $4.1 million and $6.0 million for the three and six months ended June 30, 2018, respectively, consisting of general and administrative (G&A) expenses of approximately $2.7 million and $4.1 million, respectively; and research and development (R&D) expenses of approximately $1.5 million and $1.9 million, respectively.
  • For the previous year, total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of G&A expense of approximately $1.1 million and $2.2 million, respectively, and R&D expenses of $0.8 million and $1.4 million, respectively.

Steve Quay, President, and CEO commented, “We have made tremendous progress with our clinical programs. We opened enrollment in two phase 2 clinical studies: one study using our proprietary topical Endoxifen for breast density reduction, and another study using our proprietary oral Endoxifen for reducing breast cancer tumor cell activity in the “window of opportunity” between diagnosis of breast cancer and surgery. We also completed dosing and patient visits in our phase 1 study of topical Endoxifen in men. Our intraductal microcatheter immunoOncology pre-clinical program was launched and we contracted with an additional manufacturer for Endoxifen. We have had a very busy and productive first six months of 2018 as we continue the momentum in the advancement of our clinical programs. We are looking forward to announcing preliminary results from our phase 1 study of topical Endoxifen in men by September 30, 2018.”

 

 

 

 

 

 

Analyst Update

Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report recently and maintained his “Buy rating” and his $10/price target.

 

 

 

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

SEATTLE, Aug. 13, 2018– Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced …..

finance.yahoo.com

Read Full Article



“Got Turkey?” Vista Partners Weekly Market Update 8-11-18

Vista Partners has published “Got Turkey?” Vista Partners Weekly Market Update 8-11-18 and is accessible on our Newsletters Page. Each issue is written by the Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Staying On Course?” Vista Partners Weekly Market Update 8-4-18

Vista Partners has published “Staying On Course?” Vista Partners Weekly Market Update 8-4-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Breast Cancer Innovator Atossa Genetics Has Added Alchem Laboratories As Second Manufacturer to Supply “Increasing Need” Of Endoxifen

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced this week that is has added Alchem Laboratories as a U.S. contract manufacturer to supply Endoxifen. Subject to successful bioequivalence and other testing, the material will be used to produce both oral and topical drug product presentations.

Alchem Laboratories is located in Gainesville, Florida. It has supplied APIs for 16 active clinical studies, 13 of which were led by the National Cancer Institute (NCI) and that Alchem has been supporting through multiple R&D contracts for over fifteen years. In 2018, Alchem added oral and injectable products to its topical product manufacturing capabilities in its GMP clinical manufacturing facility expansion.

Alchem provides qualified infrastructure and trained personnel for all stages of drug development including design and synthesis of novel compounds, synthesis of analogs of lead compounds, process development and optimization, analytical method development and validation, stability studies for drugs and intermediates, cGMP manufacturing of APIs and products for clinical studies, and documentation for all stages of drug development. Its partners and collaborators include the NCI, part of the National Institutes of Health (NIH), the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Acquisition Activity (USAMRAA), the U.S. Department of Agriculture (USDA), the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (ICP), Gemphire Therapeutics, Inc., Cerenis Therapeutics Holding SA, Brickell Biotech, Inc., FLUCEL LLC, Nanopharmaceutics, MRIGlobal, Pace Analytical Labs, Southern Research, and the University of Florida UF|INNOVATE – Sid Martin Biotech.

Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa. stated, “Our needs for the ongoing clinical supply of Endoxifen are dramatically increasing as we advance our clinical studies. As a second Endoxifen manufacturer, Alchem will begin supplying Endoxifen for one or more of our studies slated for later this year. They will be an excellent partner, with their experience and capabilities, to ensure we are poised to move our development programs forward quickly, particularly in the U.S.”

Here is a list of Atossa’s clinical programs that are using its proprietary Endoxifen include:

  • Phase 2 study to determine if oral Endoxifen reduces tumor activity in early stage breast cancer patients in the “window of opportunity” between diagnosis of breast cancer and surgery (now open for enrollment in Australia)
  • Phase 2 study to determine if topical Endoxifen reduces mammographic breast density (now open for enrollment in Sweden)
  • Phase 1 study of topical Endoxifen in men (enrollment and dosing complete; results to be announced this quarter)
  • Phase 2 study of topical Endoxifen to treat gynecomastia in men being treated for prostate cancer (study targeted to open in Q4 2018)
  • Phase 2 study of oral Endoxifen for patients who are “refractory” to Tamoxifen (study targeted to open in 2H 2018)

Analyst Update

Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report recently and maintained his “Buy rating” and his $10/price target.

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that is has added Alchem Laboratories as a U.S. contract manufacturer to supply Endoxifen..

finance.yahoo.com

Read Full Article



Listen to The Groundwork Forum Podcast Interview of Kyle Guse CFO of Atossa Titled “An Overview of Breast Cancer Treatment Innovator Atossa Genetics”

The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives on key issues; to create a powerful, global network in order to strengthen the influence throughout the world; to draw up innovative and concrete action plans to encourage contribution to society; and to promote diversity in the business world.

The most recent Groundwork Forum Podcast Episode features an interview with Seattle-based Atossa Genetic’s CFO Kyle Guse and is titled “An Overview of Breast Cancer Treatment Innovator Atossa Genetics.” Atossa Genetics Inc. (NasdaqCM: ATOS) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

To listen to the podcast, visit https://www.vistapglobal.com/groundwork-forum/.

Fans of the podcast can contact inquiries@vistapglobal.com via email or provide feedback and ideas for the podcast.

Based in San Francisco the Groundwork Forum is hosted by John Heerdink, Managing Director of Vista Partners LLC. The Groundwork Forum is released periodically and is available for free at https://www.vistapglobal.com/groundwork-forum/.

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, The Groundwork Forum Podcast and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies, Vista’s Featured Companies, International Companies, Pre-IPO Companies & Strategic Companies.

Contact:

inquiries@VistaPGlobal.com

 

 




“Snapshot” Vista Partners Weekly Market Update 7-28-18

Vista Partners has published “Snapshot” Vista Partners Weekly Market Update 7-28-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Vista Partners Publishes July’s FREE Macroeconomic & Investment Monthly Newsletter

Vista Partners (“Vista”) has published July’s FREE Macroeconomic & Investment Monthly Newsletter, “Economy & Market Maintaining Highs.”

Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Mining, Materials, Nuclear Energy, Real Estate, and Technology.

Vista Partners centers its Coverage on the Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies, with exclusive, broad-based commentary from Managing Director, John F. Heerdink, Jr.

In July’s edition of the Macroeconomic & Investment Newsletter, Mr. Heerdink states,

“Speaking of bonds—and not the 007 variety—, back at home, the yield curve, which measures the difference between shorter- and longer-term Treasury yields—is….”Read full newsletter.

Companies Featured in July’s Newsletter: Atossa Genetics, Inc. (NASDAQ: ATOS) | Disney (DIS) | | Fusion, Inc.(NASDAQ: FSNN) | Google (Alphabet) (GOOG) | Pfizer (PFE) & UnitedHealth Group (UNH).

Vista Partners publishes 100% of its content free. Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. To receive FREE email updates from Vista, please sign up at VistaPGlobal.com/signup.

About Vista Partners LLC:

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.comwith daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies, Vista’s Featured Companies, International Companies, Pre-IPO Companies & Strategic Companies.

Contact:

inquiries@VistaPGlobal.com




“All Good?” Vista Partners Weekly Market Update 7-21-18

Vista Partners has published “All Good?” Vista Partners Weekly Market Update 7-21-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Breast Cancer Innovator Atossa Genetics Advancing Intraductal Microcatheter Immunotherapy Program Via Pre-clinical Studies With Translational Drug Development, LLC

Seattle based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,  Atossa Genetics Inc. (ATOS) recently announced that they are advancing their intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC (“TD2”).  TD2 supports oncology-focused companies by providing a unique and translational set of services to accelerate drug development. Using a dedicated team of professionals with broad experience and understanding of drug development, TD2 applies thorough and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. For more information, visit www.TD2inc.com.

The purpose of the initial study is to develop and validate preclinical methods of using Atossa’s proprietary intraductal microcatheter technology to administer immunotherapy to the site of tumor initiation.

Steve Quay, Ph.D., MD, President and CEO of Atossa stated, “While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer.  We are, however, encouraged by a recent case study reported June 4, 2018 in Nature Medicine (N. Zacharakis, et al.), in which a patient with metastatic breast cancer who was not responding to chemotherapy had complete tumor regression 22 months after being treated with an intravenous infusion of eighty billion T-cells and interleukin. We believe our proprietary intraductal microcatheter technology may provide a unique and more efficacious and cost-effective treatment method by delivering a significantly smaller number of T-cells directly to the site of the cancer prior to metastasis, rather than through the bloodstream, where they are diluted into the entire body. These studies are the first of several steps to develop our intraductal microcatheter technology to treat breast cancer with cell-based immunotherapy, such as CAR-T. These pre-clinical studies will form the basis for the design of human studies, with the ultimate goal of treating breast cancer by administering an immunotherapy with our proprietary microcatheter technology.”

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical..

finance.yahoo.com

Read Full Article